Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Body mass index (BMI):~greater than or equal to 27.0 kg/m\^2 with the presence of at least one of the following weight-related complications (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease OR greater than or equal to 30.0 kg/m\^2~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral semaglutide (Type: EXPERIMENTAL): Participants will receive once daily semaglutide tables in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68)
- Oral semaglutide placebo (Type: PLACEBO_COMPARATOR): All participants are given once daily dose for 68 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).